CD4 and cancer: Interestingly, we observed not only an overall increase in CXCL9 in cancer, but also a significant increase in ER‐negative subtypes compared to luminal A cancers, and these levels correlated significantly with levels of the TIL‐related markers CD8A, CD4, and CD5.